EP0666867A1 - Reactifs et procedes de traitement de l'arthrite rhumatoide - Google Patents
Reactifs et procedes de traitement de l'arthrite rhumatoideInfo
- Publication number
- EP0666867A1 EP0666867A1 EP93921548A EP93921548A EP0666867A1 EP 0666867 A1 EP0666867 A1 EP 0666867A1 EP 93921548 A EP93921548 A EP 93921548A EP 93921548 A EP93921548 A EP 93921548A EP 0666867 A1 EP0666867 A1 EP 0666867A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dqw2
- patients
- antigen
- rheumatoid arthritis
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 81
- 239000003153 chemical reaction reagent Substances 0.000 title description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 185
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 107
- 239000000427 antigen Substances 0.000 claims abstract description 97
- 102000036639 antigens Human genes 0.000 claims abstract description 97
- 108091007433 antigens Proteins 0.000 claims abstract description 94
- 108700028369 Alleles Proteins 0.000 claims abstract description 34
- 230000006044 T cell activation Effects 0.000 claims abstract description 9
- 150000001413 amino acids Chemical group 0.000 claims description 81
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 50
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 108091008874 T cell receptors Proteins 0.000 claims description 31
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 30
- 230000008707 rearrangement Effects 0.000 claims description 25
- 230000004913 activation Effects 0.000 claims description 22
- 230000003993 interaction Effects 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 8
- 230000030741 antigen processing and presentation Effects 0.000 claims description 7
- 230000002085 persistent effect Effects 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000012085 chronic inflammatory response Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 37
- 230000014509 gene expression Effects 0.000 abstract description 21
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000003278 mimic effect Effects 0.000 abstract description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 80
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 72
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 31
- 201000010099 disease Diseases 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 21
- 230000002163 immunogen Effects 0.000 description 15
- 208000023275 Autoimmune disease Diseases 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 238000007852 inverse PCR Methods 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 230000005784 autoimmunity Effects 0.000 description 10
- 238000010804 cDNA synthesis Methods 0.000 description 10
- 102000054766 genetic haplotypes Human genes 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 108010079317 prolyl-tyrosine Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 3
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 101710175243 Major antigen Proteins 0.000 description 3
- 101150076359 Mhc gene Proteins 0.000 description 3
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- OIDKVWTWGDWMHY-RYUDHWBXSA-N Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 OIDKVWTWGDWMHY-RYUDHWBXSA-N 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 2
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008709 cellular rearrangement Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- -1 e.g. Chemical group 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- LBJYAILUMSUTAM-ZLUOBGJFSA-N Ala-Asn-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O LBJYAILUMSUTAM-ZLUOBGJFSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- KSBHCUSPLWRVEK-ZLUOBGJFSA-N Asn-Asn-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KSBHCUSPLWRVEK-ZLUOBGJFSA-N 0.000 description 1
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
- UYCPJVYQYARFGB-YDHLFZDLSA-N Asn-Phe-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UYCPJVYQYARFGB-YDHLFZDLSA-N 0.000 description 1
- SUIJFTJDTJKSRK-IHRRRGAJSA-N Asn-Pro-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SUIJFTJDTJKSRK-IHRRRGAJSA-N 0.000 description 1
- QYRMBFWDSFGSFC-OLHMAJIHSA-N Asn-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QYRMBFWDSFGSFC-OLHMAJIHSA-N 0.000 description 1
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 1
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 1
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 1
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- JVWPPCWUDRJGAE-YUMQZZPRSA-N Gly-Asn-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JVWPPCWUDRJGAE-YUMQZZPRSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- RHRLHXQWHCNJKR-PMVVWTBXSA-N Gly-Thr-His Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 RHRLHXQWHCNJKR-PMVVWTBXSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010037799 HLA-DQ1 antigen Proteins 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- BXOLYFJYQQRQDJ-MXAVVETBSA-N His-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)N BXOLYFJYQQRQDJ-MXAVVETBSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- BCVIOZZGJNOEQS-XKNYDFJKSA-N Ile-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)[C@@H](C)CC BCVIOZZGJNOEQS-XKNYDFJKSA-N 0.000 description 1
- GLYJPWIRLBAIJH-FQUUOJAGSA-N Ile-Lys-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N GLYJPWIRLBAIJH-FQUUOJAGSA-N 0.000 description 1
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- TVEOVCYCYGKVPP-HSCHXYMDSA-N Leu-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N TVEOVCYCYGKVPP-HSCHXYMDSA-N 0.000 description 1
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- JZMGVXLDOQOKAH-UWVGGRQHSA-N Lys-Gly-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O JZMGVXLDOQOKAH-UWVGGRQHSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102100025912 Melanopsin Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- OBVHKUFUDCPZDW-JYJNAYRXSA-N Met-Arg-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OBVHKUFUDCPZDW-JYJNAYRXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- HBGFEEQFVBWYJQ-KBPBESRZSA-N Phe-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HBGFEEQFVBWYJQ-KBPBESRZSA-N 0.000 description 1
- NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 1
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 1
- SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 206010062164 Seronegative arthritis Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- SWIKDOUVROTZCW-GCJQMDKQSA-N Thr-Asn-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O SWIKDOUVROTZCW-GCJQMDKQSA-N 0.000 description 1
- OHAJHDJOCKKJLV-LKXGYXEUSA-N Thr-Asp-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OHAJHDJOCKKJLV-LKXGYXEUSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009210 ongoing activation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010058119 tryptophyl-glycyl-glycine Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention is directed to reagents which are capable of preventing, suppressing, or treating immune-related disease such as autoimmune disease.
- the invention is directed to peptides derived from major histocompatibility complex HLA molecules, T cell receptors, and other autologous antigens responsible for autoimmunity in rheumatoid arthritis.
- the invention is also related to antibodies directed against the MHC antigen- presenting molecule.
- the HLA system of antigens is controlled by genes located on the short arm of chromosome 6 in the major histocompatibility complex (MHC) region. This region has well-defined counterparts in other mammals such as mouse, dog, horse, pig, rat, and guinea pig.
- MHC major histocompatibility complex
- the HLA antigens are composed of two major classes: class I and class II. Class I and class II antigens differ in their biochemistry, cellular distribution, expression, and function. For a detailed examination of these features, see Dorf, M.E., ed., The Role of the Major Histocompatibility Complex in Immunobiology, New York: Garland STPM
- class I and class II molecules consist of a 44,000 kd heavy chain noncovalently bound to
- Class I molecules are ubiquitously distributed and appear on the surface of all cells, whereas class II molecules are restricted to B-lymphocytes, monocytes, macrophages, dendritic cells, Langerhans cells of the skin, and activated T cells.
- Class I molecules transport endogenous antigens, such as viral antigens, through the Golgi apparatus to the cell surface, whereas class II molecules transport endocytosed exogenous antigens, such as bacterial antigens, through the lysosomal/endosomal system.
- Class I molecules interact primarily with cytotoxic (CD8 + ) T-cells, whereas class II molecules interact with helper (CD4 + ) T-lymphocytes (Bjorkman, P.J., et al , Ann. Rev. Biochem. 59:253- 288 (1990)).
- HLA DQ antigens are relevant to the present invention, since the association with autoimmune disease presented herein is with this HLA antigen.
- the HLA D region on the short arm of chromosome 6 has been subdivided into several subregions, including DR, DQ and DP. The subdivision is classically defined by serologic and cellular typing methods, and recently has been defined by biochemical and molecular analyses.
- HLA-Al is the 1 allele at the HLA-A locus.
- Alleles that have been tentatively assigned to a given locus but are not yet officially recognized are designated by a "w" (for "workshop") placed before the number, for example, HLA-DQw2.
- w for "workshop" placed before the number, for example, HLA-DQw2.
- the HLA system is extremely polymorphic, having multiple different alleles at each known locus. For example, there are at least 23 distinct alleles at the HLA-A locus, and at least 47 distinct alleles at the HLA-B locus. Each allele determines a product.
- the products of the HLA-A, -B, -C, -D, -DR, -DQ and -DP alleles are cell surface molecules that bear the antigenic determinants.
- haplotype Since one chromosome is inherited from each parent, there are two HLA haplotypes. Because all HLA genes are co-dominant, both alleles at a given HLA locus are expressed, and two complete sets of HLA antigens can be detected on cells.
- the HLA type of an individual is usually given as the phenotype and designates all HLA antigens possessed by the individual, for example, HLA-Al, -A2, -B7, -B12, -Cwl, -Cw2, -Dw2,
- the DQ a and ⁇ chains have 234 and 229 amino acids, respectively.
- the DQ genomic subregion contains two chain genes and two ⁇ chain genes.
- T cells The thymus derived lymphocytes (T cells) mediate two general types of immunologic functions: effector and regulatory. Effector functions include delayed hypersensitivity, allograft rejection, tumor immunity, and graft-versus- host reactivity. These effector functions reflect the ability of T lymphocytes to secrete proteins called lymphokines, and the ability to kill other cells (referred to as "cytotoxicity").
- the regulatory functions of T cells are represented by their ability to amplify cell-mediated cytotoxicity by other T cells and immunoglobulin production by B cells. T cells are antigen-specific. The specificity is the result of receptor molecules that are capable of recognizing antigen.
- the receptor consists of two chains: an acidic chain (molecular weight 45,000-55,000) and a more basic ⁇ chain (molecular weight 40,000-50,000), which are linked by a disulfide bond on the T cell surface. Both and ⁇ chains are integral membrane proteins. Both chains can be divided into variable and constant region domains. The variable region interacts with antigen, and thus the amino acid sequences of the variable region of different antigen-specific T cell clones are different. The amino acid sequences of the constant region from these same clones are similar. This general structure is analogous to the variable and constant region domains noted for immunoglobulin molecules.
- the genetic loci encoding the T cell receptor genes can be divided into the following regions: variable region genes (V), diversity segment genes (D), joining region genes (J), and constant region genes (C).
- V, D and J regions represent gene clusters. There are approximately 100 different V region genes for the a chain and around 80 different V region genes for the ⁇ chain. There are at least two D region genes for the ⁇ chain. There are around 100 J region genes for the a chain and 13 J region genes for the ⁇ chain. There is 1 C region gene for the a chain and 2 C region genes for the ⁇ chain. Rearrangements occur among these genes in a fashion analogous to that demonstrated for immunoglobulin genes. This provides the diversity to account for the existence in each individual of more than 1 million distinct T cell clones, each of which has a different antigen specificity.
- the / ⁇ T cell antigen receptor heterodimer does not recognize soluble antigen alone.
- the antigen receptor recognizes antigen in conjunction with products of MHC genes.
- recognition occurs in conjunction with class II molecules.
- recognition is in conjunction with class I molecules.
- large soluble antigens are processed by an appropriate accessory cell, such as a macrophage or dendritic cell.
- the sequence of events involved in T cell recognition of antigen is as follows.
- the antigen is phagocytosed by an antigen-presenting cell, internalized, processed, and then a peptide is expressed on the cell surface in conjunction with class I or class II MHC molecules.
- the T cell antigen receptor heterodimer then recognizes the antigen plus the MHC gene product.
- T cell activation The events required for T cell activation are as follows. Interaction between the antigen receptor complex on the T cell and antigen plus MHC gene products on accessory cells generates biologically active metabolites from membrane inositol. Another signal, initiated by interleukin-1, is sometimes required. In order for T cell activation (as measured by T cell proliferation) to proceed to completion, secretion of interleukin-2 must occur, and enhanced expression of the receptors for interleukin-2 must also occur. Interleukin-2 acts as an autocoid as it expands the particular T cell clone. Once T cells are activated by the signals required for antigen-specific activation, they can release lymphokines. These lymphokines act in an antigen-nonspecific fashion on other populations of mononuclear cells.
- autoimmune disease may result from a wide spectrum of genetic and immunologic abnormalities which differ from one individual to another and may express themselves early or later in life depending on the presence or absence, respectively, of many superimposed exogenous or endogenous accelerating factors.
- the disease process may be caused, among other things, by sensitized T lymphocytes. These lymphocytes produce tissue lesions by poorly understood mechanisms which may involve the release of destructive lymphokines or which attract other inflammatory cells to the lesion.
- Rheumatoid arthritis a major autoimmune disease, is characterized by the presence in serum of autoantibodies directed against the Fc portion of IgG.
- Such autoantibodies usually of IgM or IgG isotype, combine with IgG to form immune complexes that are considered to participate in the associated synovitis and vasculitis via activation of the complement cascade and attraction of polymorphonuclear cells to the sites of their deposition.
- Some rheumatoid factors cross-react with other autoantigens, such as DNA, histones, and cytoskeletal elements.
- Joint pathology characterized by inflammation and joint destruction, is the result of a complex interaction of cellular events (inflammatory cells, immunocompetent cells, and synovial lining cells) and their secreted products
- the synovial tissue (pannus) in rheumatoid arthritis has the appearance of a hypercellular lymphoid organ in which the predominant lymphocytes are T cells, which make up 80% of the synovial tissue lymphocytes (Bankhurst et al. , Arthritis and Rheumatism 79:555 (1976); Kurosaka, J. Exp. Med. 758: 1191 (1983)).
- T cell function In addition to the preponderance of T cells in the synovial pannus and an increased number of these T cells being activated in vivo, evidence for defects in T cell function and proportions have been described. Importantly, therapeutic measures that alter T cell function, such as total nodal lymphoid irradiation, significantly improve the clinical disease state, but are associated with marked toxicity (Kotzin et al , N. Engl. J. Med. 305:969 (1981)).
- HLA molecules and T cell receptors allow the immune system to distinguish self from foreign antigens through a selection process occurring in the thymus (Dorf, M.E., ed., The Role of the Major Histocompatibility Complex in Immunobiology , New York: Garland STPM Press, 1981; Sullivan, K.A., et al , The HLA System and Its Detection," in: Rose, N.R., et al , eds., Manual of Clinical Laboratory and Immunology, pp. 835-846, Washington, DC, American Soc. for Microbiology, 1986; Braun, W.E., Clin.
- HLA alleles have been significantly associated with a number of diseases (Braun, W.E., HLA and Disease: A Comprehensive Review, Boca Raton, FL, CRC Press, 1979; Tiwari, J.L., et al , HLA and Disease, New York, Springer-Verlag, 1985). These include HLA-DR2 in narcolepsy,
- HLA-B27 in ankylosing spondylitis, and sero-negative arthropathies and HLA-DR3 with -DR4 in diabetes mellitus.
- class II structural polymorphism may mediate disease susceptibility (Nepom, G.T., et al , Ann. Rev. Immunol. 9:493-525 (1991)).
- Polymorphic residues in the class II molecule might differentially bind a putative autoantigen peptide and present it to the responding T lymphocytes.
- the spectrum of expressed T cell receptors might be different in individuals with different class II genotypes.
- Autoreactive T cell receptors capable of recognizing an autoantigen class II complex would more likely be selected by thymic epithelium which expressed the nonsusceptible class II antigen.
- homologous regions could serve as an autoantigenic target with an immune response to the (bacterium or) virus leading to attack of self-cells expressing relevant class (I or) II products" (Nepom, G.T., et al.. Ann. Rev. Immunol. 9:493-525 (1991)).
- rheumatoid arthritis has strong associations with class II antigens, Dw4 as defined by homozygous typing cells (HTC), and DR4 defined serologically.
- Amino acids 70-74 of the DR ⁇ chains of DR1 (Dwl), DR4 (Dw4), DR14 (Dwl4), and DR15 (Dwl5) are essentially the same as the segment of the gpl 10 protein of the Epstein-Barr virus (except for a minor substitution of arginine for lysine at position 71) (Braun, W.E., HLA and Disease: A Comprehensive Review, Boca Raton, FL, CRC Press, 1979). For these reasons, scientific investigators, searching for the causative agent for rheumatoid arthritis, have postulated that immune disregulation associated with the disease may be associated with specific genes of the major histocompatibility complex.
- the disease may be associated with clonally expanded T cells detectable as a skewing of the peripheral ⁇ T cell antigen receptor repertoire.
- U.S. Patent No. 4,886,783 describes a method of diagnosing autoimmune diseases, including rheumatoid arthritis, based upon an expansion of V/3 gene usage in the total population of T lymphocytes in rheumatoid arthritis patients.
- PCT International Publication No. 90/06758 which broadly covers monoclonal antibodies reactive with epitopes on the T cell antigen receptor that can be used in the diagnosis and treatment of many immune related diseases, associates rheumatoid arthritis with an increased percentage of T cells which express V ⁇ l, V/33, V/39, or V01O T cell receptor variable regions in a patient sample. Methods of diagnosing and treating rheumatoid arthritis patients with monoclonal antibodies specific for these gene products are described.
- Copending patent application 07/750,986 describes the detection of a subset of individuals afflicted with rheumatoid arthritis using a reagent having specificity for a unique sequence within the variable region of the a chain of the T cell receptor for antigen, and specifically for V ⁇ .12.1.
- the application discloses the expression of the V ⁇ .12.1 gene product on CD8 + T lymphocytes that is expanded in a subset of rheumatoid arthritis patients when compared to the expression of V ⁇ .12.1 on CD8 + lymphocytes of normal, healthy subjects that do not have the immune abnormality. This expression thereby enables the detection of this subset of patients with reagents that bind specifically to V ⁇ .12.1 sequences.
- Approaches based on this principle include vaccination with whole T cells, passive blockade using antibodies which bind to the TCR, passive blockade using antibodies that bind to the MHC portion of the complex, administration of antibodies reactive with the T cell markers (e.g., CD4 + , CD8 + ), and the use of peptides which mimic the antigen of interest and compete for binding to the MHC or the TCR molecule.
- T cell markers e.g., CD4 + , CD8 +
- T cells expressing the TCR ⁇ heterodimer can induce idiotypic and V gene family-specific antibodies that can regulate T cell function (Owhashi, M., et al, supra; Gascoigne, N.R.J., et al, Proc. Natl Acad. Sci. USA 84:2936 (1987); Kappler, J.W., et al, Nature 332:35 (1988); Kappler, J.W., et al. , Cell 49:263 (1987); MacDonald, H.R. , et al. , Nature 332:40 (1988)).
- antibodies that recognize the TCR V/38 sequence have been effective in the prevention and treatment of autoimmunity in mice and rats (Owhashi, M., et al, supra; Acha-Orbea, H., et al, Cell 54:263-213 (1988); Urban, J., et al, Cell 54:511-592 (1988)).
- Obtaining such antibodies selective for V region gene products has been dependent upon the availability of T cell clones that express TCR encoded by the relevant V gene family, and requires a laborious screening procedure using whole cells to establish specificity.
- the protective state was termed "counter-autoimmunity. " This state involves T cell clones which can specifically proliferate in response to the vaccinating T cells, can suppress effector clones in vitro (non-specifically, presumably through release of a suppressive lymphokine), and can adoptively transfer counter-autoimmunity in vivo. Such counter-autoimmunity is accompanied by suppressed delayed hypersensitivity (DH) responses to the specific epitope and prevention or remission of clinical disease.
- DH delayed hypersensitivity
- T cell "vaccine” preparations to be useful in humans, must be both autologous and individually specific, that is, uniquely tailored for each patient. Furthermore, the presence of additional antigens on the surface of such T cells may result in a broader, possibly detrimental, immune response not limited to the desired T cell clones (Offner, H., et al, J. Neuroimmunol. 27: 13-22 (1989)).
- agents and pharmaceutical compositions which have the properties of specificity for the targeted autoimmune response, predictability in their selection, convenience and reproducibility of preparation, and sufficient definition to permit precise control of dosage.
- the present invention is based upon the applicants' discovery that a subset of rheumatoid arthritis patients have a marked expansion of Vc.12.1 bearing CD8+ T cells, and that a high frequency of these patients share the extended HLA DQw2 haplotype.
- Molecular analysis of the T cell receptors in each of three unrelated patients with V ⁇ .12.1 elevation revealed antigen- driven clonal expansions.
- the frequency of HLA DQw2 was 86%.
- the invention is directed to reagents that block the normal interaction of HLA DQw2 antigen with T cell receptors, and particularly the T cell receptors bearing the V ⁇ l2.1 rearrangement, and to methods of using the reagents.
- the methods of the present invention are directed to administering
- DQw2 antibody to DQw2 rheumatoid arthritis patients and particularly rheumatoid arthritis patients bearing T cell receptors containing the V ⁇ .12.1 rearrangement.
- the methods of the present invention use a monoclonal antibody against the DQw2 antigen.
- reagents of the invention include peptides, preferably of around 8-24 amino acids, that represent alterations of the normally processed endogenous antigens that are causally related to autoimmunity in rheumatoid arthritis.
- peptides may be derived from the DQw2 molecule itself which is being recognized as a "nonself" antigen and presented either by DQw2 itself as the MHC molecule on an effector cell or by another MHC antigen presenting molecule.
- the peptide may be derived from the T cell receptor V ⁇ l2.1 gene product.
- the autoantigen When the autoantigen is established to be a portion of DQw2 itself, this portion is altered such that it is recognized by the DQw2 on the antigen presenting cell and either displaces the toxic autoantigen, prevents further binding of the DQw2 present on the antigen presenting cell with the toxic autoantigen, or otherwise interferes with T cell activation. This competition or displacement thus prevents the further activation of T cells which were specific for the offending autoantigen.
- the peptide may be derived from V ⁇ .12.1 and used for essentially the same purposes.
- the offending autoantigen may be recovered and the peptide sequenced. Subsequently, altered sequence variants of the relevant autoantigen peptide may be prepared to either displace or compete with the true endogenous offending autoantigen.
- the peptides so prepared may then be used as a treatment to ameliorate the symptoms of rheumatoid arthritis in DQw2 patients with rheumatoid diseases, particularly rheumatoid arthritis.
- the invention is further directed to nucleic acid sequences corresponding to the peptides of the present invention which can be cloned into appropriate expression vectors such that the peptides are produced in sufficient amounts to be therapeutically useful.
- the peptides can be synthesized by standard chemical synthetic procedures. Brief Description of the Figures
- Figure 1. Major histocompatibility complex HLA genes.
- Figure 2. Expansion of V ⁇ .12 bearing T cells in rheumatoid arthritis patients.
- A Flow cytometric analysis was performed using directly conjugated antibodies. Heparinized blood was obtained from individuals and
- PBMC peripheral blood mononuclear cells
- Lymphocytes were gated on the basis of forward and side scatter profiles (not shown) and analyzed for fluorescence intensity in log scale. Ten thousand viable cells were analyzed by gating on lymphocytes excluding propidium iodide. The data was analyzed by dividing the dot plot into quadrants to represent unstained cells (lower left, quadrant 3), cells stained with FITC alone (OKT4 or OKT8) (lower right, quadrant 4), cells stained with FE alone (6D6) (upper left, quadrant 1), and cells that were co-stained with
- FIG. 3 Predicted amino acid sequences of the V ⁇ l2 containing transcripts.
- Nucleotide sequences of V ⁇ .12.1 containing transcripts was generated by direct (V ⁇ l2.1-specific) or by iPCR (all V ⁇ s) and cloned into M13 vector. Separation of CD4 + and CD8 + T cells was carried out on Ficoll- Paque (Pharmacia Fine Chemicals, " in Uppsala, Sweden) isolated PBMC and suspended in RPMI-1640 containing 5% FCS at 5xl0 5 /ml to mix with saturating amounts of anti-CD4 (OKT4) or anti-CD8 (OKT8 and 89.2) mAb.
- Ficoll- Paque Pharmacia Fine Chemicals, " in Uppsala, Sweden
- T cells are enriched to greater than 98% purity as verified routinely by staining the negatively selected populations by FACS (i.e., OKT4 or OKT8 depleted cell populations).
- Second step of selection with anti-V ⁇ l2.1 (mAb 6D6) was carried out on CD4-depleted (CD8-enriched) cells in order to isolate V ⁇ l2.1/CD8 + T cells to make RNA and use in the iPCR method.
- RNA from CD8 + or V ⁇ l2.1 + /CD8 + T cells was carried out according to Chomczynski et al. ⁇ Anal Bioch. 762: 156 (1987). Total RNA was quantitated and analyzed for intactness by resolving on a 1 % agarose mini-gel and visualized by staining with EtBr.
- Complementary DNA (cDNA) for the direct PCR method was synthesized in a reverse transcription reaction using reverse transcriptase and 1-5 ug of total RNA by priming with 500 ng of oligo-(dT) g primer.
- V ⁇ s, V ⁇ s and J ⁇ s gene segments present in the V ⁇ l2.1 + /CD8 + T cells were identified by a second method that does not require prior sequence information on both ends of the DNA to be amplified.
- This technique independently confirmed findings generated by the direct PCR method, and provided new sequence information on V ⁇ , J ⁇ and chain usage.
- Inverse PCR (iPCR) was first established to amplify the flanking region of a known sequence within a given restriction fragment of genomic DNA. Recently, this method was shown to be applicable to the amplification of the full length cDNA of TCR ⁇ and ⁇ genes.
- First strand cDNA was synthesized from RNA of T lymphocytes by priming with an olig-(dT) 8mer , using Moloney murine leukemia virus derived reverse transcriptase lacking RNase H activity.
- RNase H was used to nick the mRNA strand of the RNA/DNA hybrid, generating a series of RNA primers that serve to synthesize the second strand DNA with E. coli DNA polymerase I and E. coli DNA ligase.
- the double-stranded cDNA was blunt ended using the 3 '-5' exonuclease activity of T4 DNA polymerase and the DNA was then circularized using T4 DNA ligase.
- This circular cDNA was used as the template for the iPCR amplification by using a pair of C ⁇ or C ⁇ primers, which are oriented in an outward direction from one another.
- This method generated PCR products of approximately 700 bp for the TCR ⁇ chain, and for the TCR3 chain, a major (700 bp) and a minor (approximately 400 bp) corresponding to the expected VDJC/3 and DJC/3 transcript lengths.
- This method generated up to 2xl0 6 primer specific cDNA clones starting with as little as 1 ug of total RNA
- a library could be generated of TCR ⁇ or cDNA products from RNA isolated from as little as 2x10 of fresh peripheral T cells.
- One of the two primers contained an artificial Sal I site and the other primer contains a Not I site, which facilitated DNA cloning and sequencing. Restriction sites in the PCR primers were used to generate sticky ends for cloning.
- Appropriately sized DNA products were isolated from low melting point (LMP) agarose gels (BRL, Gaithersburg, MD) and ligated to vector with cloning sites.
- LMP low melting point
- FIG. 4 Expanded V ⁇ l2 + T cells in rheumatoid arthritis were previously activated. The cell surface expression of DR, IL-2R ⁇ and ⁇ chains, CD45RO, HLA-1 and transferrin receptor were analyzed by immunofluorescence staining as described in Figure 2. The graph represents relative expression amongst CD3 + , CD4 + , CD8 + and V ⁇ l2 + T cells.
- LB3 .1 (anti-HLA DR), 84.19.9 (anti-IL-2R ⁇ ), Tu27 (anti-IL-2R ⁇ ), UCHL1 (anti-CD45RO), TS2/7 (anti-VLA-1), 5E9 (anti-transferrin receptor) were used at 1/100 ascites dilution with a second antibody (goat anti-Mouse immunoglobulin) conjugated with FITC or PE.
- the present invention is directed to reagents and methods based on the human T cell receptor V ⁇ l2.1 rearrangement and the DQw2 haplotype for treating humans suffering from rheumatoid arthritis.
- an object of the present invention is to provide compositions, pharmaceutical formulations, and methods useful for treating humans suffering from rheumatoid arthritis.
- a still further object of the invention is to provide compositions, pharmaceutical formulations, and methods useful for preventing or attenuating the clinical symptoms of rheumatoid arthritis.
- the invention is directed to a peptide comprising an amino acid sequence (I) that is analogous to an amino acid sequence (II) that is presented to a T lymphocyte, in rheumatoid arthritis patients, by an MHC- bearing antigen-presenting cell, wherein amino acid sequence II is derived from the DQw2 protein.
- amino acid sequence (I) is intended a sequence which is recognized by and bound to a major histocompatibility antigen on an antigen presenting cell.
- amino acid sequence (II) is a processed peptide derived from a naturally occurring protein in these patients which is treated by the patient's immune system as a nonself antigen, processed, and presented to a T lymphocyte by an MHC-bearing antigen presenting cell as a foreign antigen. This presentation thus activates specific T lymphocytes to complete an immune response against the patient's own protein.
- amino acid sequence I is designed to bind the major histocompatibility antigen present on the antigen presenting cell, displacing the processed self peptide or preventing the binding of the processed self peptide to the major histocompatibility molecule.
- the peptide of the present invention is derived from a persistent foreign antigen, including, but not limited to, viral antigens that are the result of a persistent viral infection.
- amino acid sequence I is also designed to bind the major histocompatibility antigen present on the antigen presenting cell, and displacing the foreign antigen or preventing the binding of the foreign antigen to the major histocompatibility molecule or the functional interaction with the T-cell.
- the peptide is also designed to bind to the MHC molecule but to prevent interaction of the MHC/antigen complex with a relevant T lymphocyte so as to prevent the activation and clonal expansion of this T lymphocyte.
- the alteration in the amino acid sequence of the MHC binding antigen is designed either to prevent the binding of the complex to the T cell receptor or to allow the binding of the receptor but to prevent further activation.
- amino acid sequence comprising the peptide of this invention can be used alone, or bound to, or contained within the sequence of, a longer peptide.
- the longer peptide may carry additional sequences derived from the parent protein of interest or may include sequences of an unrelated peptide, such as a carrier protein, used to enhance the binding of the amino acid sequence of interest to the MHC antigen or to enhance the interaction of the complex with a T lymphocyte.
- the peptide contains an amino acid sequence (I) derived from the MHC HLA DQw2 protein. Because this protein is expressed in the subset of rheumatoid arthritis patients with a clonal expansion of T cells bearing the V ⁇ l2.1 rearrangement, the invention is specifically directed to the use of the DQw2 derived amino acid sequence I in patients bearing the V ⁇ l2.1 clonal expansion.
- the use of the peptide is not limited to such patients, but is presumed to be effective in treating any rheumatoid arthritis patient bearing the DQw2 haplotype.
- the MHC protein is MHC HLA DQw2 itself.
- the DQw2 peptide is presented to a T lymphocyte by the MHC HLA DQw2 present on an antigen presenting cell.
- amino acid sequence II, derived from DQw2 is thus presented by the DQw2 MHC protein.
- analogs of this peptide are designed to bind to DQw2 and to thus prevent interaction with or block activation of the T cell presented with the DQw2 peptide by DQw2 itself.
- the MHC protein is other than DQw2 and may be any of the other relevant major histocompatibility proteins found on antigen presenting cells and which function to present processed DQw2 antigens to T lymphocytes.
- the peptide is bound to HLA DQw2, which peptide stimulates V ⁇ l2.1-bearing T cells.
- This peptide may be derived from any self or foreign protein if it has the properties of stimulating V ⁇ 12.1 -bearing T cells.
- the peptide contains an amino acid sequence I that is analogous to an amino acid sequence in the ⁇ chain of a T cell receptor which bears the V ⁇ l2.1 rearrangement.
- the disease-causing peptide does not require alteration. Instead, the peptide portion which is presented by a major histocompatibility complex antigen on an antigen presenting cell, is derived from an appropriate protein but is not altered in amino acid sequence. Instead, the peptide is administered in the appropriate dose so as to induce tolerance, which entails diminished T cell activity.
- the present invention is broadly directed to a method for preventing, ameliorating, or otherwise treating rheumatoid arthritis by the administration of any of the peptides described above in amounts sufficient for such amelioration, prevention, or treatment.
- the reagents of the present invention when utilized in the methods of the present invention, may act on a number of levels. Accordingly, the efficacy of the reagents includes, but is not limited to, preventing antigen presentation, preventing T cell activation, or inducing a state of anergy in the T cell population.
- the present invention is thus directed to a method for preventing antigen presentation in patients with rheumatoid arthritis, said patients expressing the MHC HLA DQw2 allele, comprising administering any of the peptides described above in amounts sufficient to prevent the presentation.
- the invention is further directed to a method for preventing T cell activation in patients with rheumatoid arthritis, which patients express the MHC HLA DQw2 allele, comprising administering any of the peptides described above in amounts sufficient to prevent the activation.
- the methods of the present invention are also broadly useful for preventing or ameliorating a chronic inflammatory response in patients with rheumatoid arthritis and expressing the MHC HLA DQw2 allele, the response resulting from the persistent activation of T lymphocytes by an MHC-bearing antigen presenting cell, particularly where the MHC is the DQw2 gene product.
- the method comprises administering any of the proteins described above in amounts sufficient to prevent the chronic inflammatory response.
- the reagents and methods of the present invention are also useful to induce tolerance which entails diminished T cell activity. This tolerance is induced by the administration of peptides derived from the appropriate antigens but not bearing alterations in amino acid sequence that is different from the offending protein.
- anergy which is the inability of the recipient T cell to react to the antigen, is induced.
- the anergy results from the tolerization of the recipient to a particular antigen, which is induced by administration of excessive amounts of the antigen.
- the peptide may also contain an amino acid sequence I derived from the ⁇ chain of a T cell receptor bearing the V ⁇ 12.1 rearrangement.
- a peptide is prepared which is analogous to the portion of the V ⁇ l2.1 which is presented by an MHC antigen to a T lymphocyte by an MHC-bearing antigen presenting cell.
- the MHC molecule may be DQw2 or any other histocompatibility antigen that functions to present antigen to T lymphocytes.
- the invention is specifically directed to the use of such a peptide in the subset of patients bearing clonal expansions of T cells containing receptors with the V ⁇ l2.1 rearrangement.
- the invention is directed to all of the hereinbefore described methods wherein the peptide comprises an amino acid sequence I derived from the V ⁇ 12.1 rearrangement.
- treatment with the peptides of the present invention that are derived from DQw2 is not restricted to patients with rheumatoid arthritis who bear the V ⁇ l2.1 clonal expansion. It is understood that the presentation of DQw2 as an antigen to T lymphocytes may occur wherein the T lymphocyte does not necessarily bear the V ⁇ 12.1 rearrangement but where the DQw2, recognized by a T lymphocyte as nonself, may be recognized by a T lymphocyte other than the lymphocyte with the V ⁇ l2.1 rearrangement such that said lymphocyte becomes clonally expanded.
- the invention is also generally directed to methods using antibody reagents wherein said antibodies are developed against the DQw2 protein itself. Accordingly, the invention is directed to a method for preventing antigen presentation in patients with rheumatoid arthritis, which patients express the MHC HLA DQw2 allele, comprising administering an antibody against the MHC HLA DQw2 protein, which is effective in blocking the interaction of a DQw2-bearing antigen-presenting cell with a T lymphocyte.
- the present invention is directed to a method for preventing T lymphocyte activation by use of the above method, a method for preventing or ameliorating a chronic inflammatory response in patients with rheumatoid arthritis and expressing the MHC HLA DQw2 allele, which response results from the persistent activation of T lymphocytes by an MHC-bearing antigen- presenting cell, by the application of the above method, and more generally, a method for treating rheumatoid arthritis in these patients.
- the antibody may be used to bind the DQw2 molecule when it functions as an antigen-bearing MHC found on an antigen- presenting cell or may be developed against a DQw2 peptide which functions as the presented antigen.
- the DQw2 functions to present a peptide derived from the processing of an endogenous protein and which is recognized by the T-lymphocytes as foreign.
- the antibody may be directed against any of those portions of DQw2 which, when bound by antibody, prevent an interaction with a relevant T lymphocyte, which interaction is necessary for the subsequent activation of that T lymphocyte.
- the antibody When the antibody is developed against the specific region of DQw2 which is presented as an antigen, the antibody likewise functions to prevent the interaction of the relevant T lymphocyte with the DQw2 peptide which has become recognized as a foreign antigen.
- the DQw2 peptide is processed by an MHC molecule on an antigen-presenting cell.
- This MHC molecule may be either DQw2 itself or may be one of the other histo ⁇ compatibility antigens which functions in presenting a relevant antigen to a T lymphocyte for a normal immune response.
- V ⁇ l2.1 protein V ⁇ l2.1 protein.
- the methods are not restricted to patients bearing
- T cells with this rearrangement are practiced in any patient with rheumatoid arthritis, which patient expresses the DQw2 haplotype.
- the invention also encompasses administration of the antibody of the present invention to patients wherein the processed peptide which is recognized as nonself may be any of a variety of autoantigens other than DQw2 and V ⁇ l2.1.
- this autoantigen is presented by an antigen-presenting cell bearing the protein gene product of the DQw2 locus.
- the methods of the present invention may be practiced either with polyclonal or monoclonal antibodies.
- treatment is meant to include both prophylactic treatment to prevent an autoimmune disease having the symptoms of rheumatoid arthritis (or the manifestation of clinical symptoms thereof) as well as the therapeutic treatment, i.e. , the suppression or any measurable alleviation of one or more symptoms after the onset of a disease presenting the symptoms of rheumatoid arthritis.
- autoantigen is intended for the purposes of the invention any substance normally found within a mammal that, in an abnormal situation, is no longer recognized as part of the mammal itself by the lymphocytes or antibodies of that mammal, and is therefore attacked by the immunoregulatory system as though it were a foreign substance.
- MHC or “major histocompatibility complex” is meant a complex series of mammalian cell surface proteins present on the surface of activated T cells, macrophages and other immune cells.
- the MHC plays a central role in many aspects of immunity, both in presenting histocompatibility (or transplantation) antigens and in regulating the immune response against conventional (foreign) antigens.
- the human MHC genes are located on human chromosome 6 and the mouse MHC genes are located in the H-2 genetic locus on mouse chromosome 17.
- the relevant MHC expression products are those that present DQw2 peptide in rheumatoid arthritis patients and in the DQw2 expression product as an antigen-presenting MHC molecule.
- Class II MHC molecules are membrane glycoproteins that form part of the MHC. Class II MHC molecules are found mainly on cells of the immune system, including B cells, macrophages, brain astrocytes, epidermal Langerhans's cells, dendritic cells, thymic epithelium, and helper T cells. Class II MHC molecules are involved in regulating the immune response during tissue graft rejection, stimulation of antibody production, graft versus host reactions, and in the recognition of self (or autologous) antigens, among other phenomena.
- T cells immune system cells derived from stem cells located within hematopoietic (i.e., blood forming) tissues.
- T cells express either the CD4 antigen (and are then called CD4+ T cells) or the CD8 antigen (in which case they are called CD8+ T cells) on their cell surface.
- CD4+ T cells express either the CD4 antigen (and are then called CD4+ T cells) or the CD8 antigen (in which case they are called CD8+ T cells) on their cell surface.
- CD8+ T cells CD8 antigens by peripheral (circulating) T cells correlates with the function and specificity of the T cell.
- T cell receptor or "TCR” is meant the antigen recognition receptor present on the surface of T cells.
- TCR is, therefore, the receptor that binds a molecule which the immune system recognizes— and presents— as an antigen (whether the molecule is foreign or autologous, the latter being the case in an autoimmune disease).
- a majority of T cells express a TCR composed of a disulfide bond and heterodimer protein containing one ⁇ and one ⁇ chain, whereas a minority of T cells express two different chains
- the TCR is composed of an ⁇ and a ⁇ chain, each of which comprises a variable and a constant region.
- the variable in turn comprises a variable, a diversity, and a joining segment.
- the junction among the variable, diversity and joining segment is postulated to be the site of antigen recognition by T cells.
- T cells initiate the immune response when antigen presenting cells (APC), such as mononuclear phagocytes (macrophages, monocytes), Langerhans's cells and follicular dendritic cells, initially take up, process (digest) and present antigenic fragments of their polypeptide on their cell surface (in connection with their MHC).
- APC antigen presenting cells
- CD4+ T cells recognize antigen molecules exclusively when the protein is processed and peptide fragments thereof are presented by APCs that express class II MHC molecules.
- T cell recognition of an antigen reflects a trimolecular interaction between the TCR, MHC molecules and peptides processed by APCs via a cleft or pocket in the three-dimensional structure of the class II MHC molecule
- the T cell receptor relevant to the present invention may be, but is not limited to, receptor expressing the V ⁇ l2.1 ⁇ variable region rearrangement.
- the T cell receptor of interest to the present invention is clonally expanded in a subset of rheumatoid arthritis patients. Accordingly, the present invention is relevant to clonally expanded populations of T cells, identified by sequencing of T cell receptor cDNA, according to the exemplary material herein, which clonal expansion has resulted from interaction with an autologous antigen (autoantigen).
- autologous antigen autologous antigen
- MHC HLA DQw2 HLA DQw2 or “DQw2” is intended that allele of a protein encoded by the DQ region in the major histocompatibility complex of genes according to Figure 1 herein. Three alleles at the DQ locus are currently known to exist. Of these three polymorphic alleles, the second has been tentatively designated as DQw2.
- amino acid sequence (I) is intended a sequence analog, which sequence is analogous to a sequence derived from a naturally occurring protein.
- the amino acid sequence (I) may be from about 8-24 amino acids in length. The significance of this amino acid sequence is that it is an analog of an amino acid sequence normally found in the body and which is presented by the MHC to a T lymphocyte.
- the amino acid sequence is analogous to that sequence in rheumatoid arthritis patients which is presented by MHC and is responsible for the T cell inflammatory response that is associated with rheumatoid arthritis.
- amino acid sequence II is intended the naturally occurring peptide that is presented to a T lymphocyte in rheumatoid arthritis patients and which is presented to T lymphocytes in such patients and is responsible for the inflammatory response characteristic of rheumatoid arthritis.
- amino acid sequence II is that portion of the DQw2 protein sequence which is presented to the T lymphocyte by the MHC.
- amino acid sequence II is that portion of the receptor sequence which is presented to a T lymphocyte by an MHC antigen, particularly the DQw2 MHC antigen.
- analog or “analogous” is intended for the purpose of the invention an amino acid sequence which is similar to a second amino acid sequence, but which alters the function of the first amino acid sequence.
- a variant of DQw2 as the antigen being presented, is altered in sequence such that it will bind to the MHC but will prevent the activation of the T lymphocyte recognizing the true DQw2 sequence either by preventing binding to the T cell receptor or, while not preventing binding, preventing subsequent steps that lead to T cell activation. In this manner, the T lymphocyte which normally recognizes DQw2 as a foreign antigen is inhibited from activation and subsequent expansion and cytotoxic effects.
- Antibodies may be prepared against soluble DQw2, DQw2 complexed with antigen, or DQw2 complexed with antigen as part of an antigen presenting cell/MHC/antigen complex.
- antibodies may be prepared against DQw2 peptides complexed with reagents rendering said peptides immunogenic.
- the amino acid sequence of the DQw2 allele is known in the art (see Figure 3, Wu et al, Human Immunol 27:305-322 (1990), which is incorporated herein by reference).
- Antibodies may be prepared in accordance with conventional techniques, particularly employing the monoclonal antibody techniques as described, for example, in U.S. Patent Nos.4,690,893; 4,713,325; 4,714,681; 4,716,111; and 4,720,459. Any of a number of techniques may be employed for identifying the presence of a T cell receptor binding to the particular monoclonal antibody or antiserum.
- a wide variety of labels have been used for detection, such as particles, enzymes, chromophors, fluorophors, chemiluminescents, and the like. Any particular label or technique which is employed is not critical to this invention, and any convenient technique may be employed.
- the techniques may either be competitive or non-competitive methodologies, including sandwich methodologies.
- the cells will usually be lysed to provide membrane-free proteins in accordance with conventional techniques. Cellular debris may be removed and the protein extracted and harvested. Alternatively, intact cells may be employed and detected by fluorescence activated cell sorting or the like.
- mice or other lower mammals may be immunized, and the genes encoding the variable regions of the antibodies specific for the region of interest isolated and manipulated by joining to an appropriate human constant region, and optionally, the complementarity determining regions used to replace the complementarity determining regions of a human antibody by genetic engineering.
- the resulting chimeric construct comprising a lower mammalian variable region or CDR and a human constant region may then be removed into a microorganism or mammalian host cell in culture, particularly a lymphocyte, and the hybrid antibodies expressed.
- mouse antibodies where tolerance can be achieved or some degree of immune suppression may be involved.
- the antibody may be formulated with conventional pharmaceutically or pharmacologically acceptable vehicles for administration, conveniently by injection.
- Vehicles include deionized water, saline, phosphate buffered saline, Ringer's solution, dextrose solution, Hank's solution, etc.
- Other additives may include additives to provide isotonicity, buffers, preservatives, and the like.
- the antibody may be administered parenterally, typically intravenous or intramuscularly, as a bolus, intermittently or in a continuous regimen.
- Typical doses for adult humans will be in the range of about 1 ng-100 mg/kg body weight.
- a preferred dosage is between about 10 ng and 10 mg/kg, and a more preferred range is between 100 ng and 1 mg/kg.
- Doses for children or other animal species may be extrapolated from the adult human doses based on relative body weight.
- a random set of overlapping peptides is synthesized from the variable domain of V ⁇ 12.1.
- DQw2 peptides random sets of overlapping peptides are synthesized from each of the following domains: ⁇ l, ⁇ 2, ⁇ l, and ⁇ 2.
- peptides are identified by releasing them from DQw2 cells of rheumatoid arthritis patients such as by acid elution or other denaturing measures as used for release of class I peptides.
- the peptides are separated by high pressure liquid chromatography and subjected to microsequencing for determination of the amino acid sequence.
- the peptide sequence to be synthesized is part of a sequence of an immunogen of interest associated with an autoimmune disease.
- the peptide sequence is that sequence which is presented by a major histocompatibility antigen to a T lymphocyte in order to induce activation of that T lymphocyte.
- the oligonucleotide comprising the subject peptide may be from any site of the immunogen sequence, that is, N terminal or C terminal proximal or central, where the oligopeptide sequence will normally be substantially homologous with from about 8-24 amino acids of the immunogen sequence, although longer sequences may also be employed.
- the difference in homology between a natural sequence and the oligopeptide which is employed will be not more than three lesions, usually not more than one lesion, which may be insertions, deletions, or conservative or non-conservative substitutions.
- compositions of this invention will include usually at least one sequence of an immunogen of interest, including the subject peptide, and may include two or more oligopeptide sequences containing sequences of from about 8-24 amino acids present in the immunogen, depending on the number of presented amino acid sequences present in the immunogen. Thus, if there are a plurality of these sequences present in the immunogen, all or fewer than all of the sequences may be employed in a single composition.
- the immunogen in preparing the subject compositions, one would select an immunogen related to the particular manifestation of autoimmunity in a patient. For example, in a patient with the V ⁇ l2.1 rearrangement and clonal expansion, the immunogen would be selected from this protein product. Similarly, in DQw2 positive rheumatoid arthritis patients, the immunogen would be selected from the DQw2 molecule. Alternatively, in DQw2 positive rheumatoid arthritis patients with a clonal expansion of a T lymphocyte containing a specific T cell receptor rearrangement, the immunogen would be said T cell receptor chain containing said rearrangement. Alternatively, the immunogen of interest may be a peptide in DQw2 positive or V ⁇ l2.1 positive patients which is other than these two proteins, but which is presented by the DQw2
- MHC or other MHC to V ⁇ l2.1 positive T lymphocytes or other lymphocytes.
- the subject oligopeptides may be administered in a variety of ways, by themselves or in conjunction with various additives.
- Various carriers may be employed which are physiologically acceptable such as water, alcohol, saline, phosphate buffered saline, sugar, mineral oil, etc.
- Other additives may also be included as stabilizers, detergents, flavoring agents, thickeners, etc.
- the amount of active ingredient administered will vary widely depending upon the particular composition, the particular host, the number and frequency of administrations, the manner of administration, age, health, etc.
- Peptides based on the sequence of DQw2, V ⁇ l2.1, or other clonally expanded T cell rearrangements and autologous peptides causing such clonally expanded T cells in rheumatoid arthritis patients can be synthesized using well known solid phase methods (Merrifield, R.B., Fed. Proc. Am. Soc. Exp. Biol. 27:412 (1962) and J. Am. Chem. Soc. 55:2149 (1963); Mitchel, A.R., et al,
- these peptides can be obtained as the expression products after incorporation of DNA sequences encoding the immunogen (or fragments or analogs thereof) into expression vectors and introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the desired peptides individually or as part of fusion peptides or proteins.
- Peptide analogs can be designed using the known amino acid sequences encoded by the genes of interest as disclosed below, using the synthetic or recombinant techniques described above and the methods of, e.g., Eyler, E.H., in Adv. Exp. Med. Biol. 95:259-281 (1978).
- a peptide having a sequence based upon the amino acid sequence of DQw2 or V ⁇ l2.1 can be chemically synthesized using the above-described techniques.
- the peptide can be tested for disease-suppressive activity when administered to a mammal using, for example, the experimental protocol of Howell, M.D., et al , Science 246:66% (1989) or Vanderbark, A. A., et al , Nahire 341:541 (1989).
- amino acid sequence variants of the peptide can be prepared by mutations in the DNA which encodes the synthesized peptide. Such variants include, for example, deletions from, or insertions and substitutions of, residues within the amino acid sequence. Any combination of deletion, insertion, and substitution may also be made to arrive at the final construct, provided that the final construct possesses the desired activity.
- these variants ordinarily are prepared by site- directed mutagenesis of nucleotides in the DNA encoding the peptide molecule, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture.
- the variants typically exhibit the same qualitative biological activity as the nonvariant peptide.
- Preparation of a peptide variant in accordance herewith is preferably achieved by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the relevant protein or peptide.
- Site-specific mutagenesis allows the production of peptide variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
- the technique of site-specific mutagenesis is well known in the art, as exemplified by Adelman et al. , DNA 2: 183 (1983).
- Typical vectors useful in site-directed mutagenesis include vectors such as the M 13 phage, for example, as disclosed by Messing et al.
- phages are readily commercially available and their use is generally well known to those skilled in the art.
- plasmid vectors that contain a single-stranded phage origin of replication may be employed to obtain single-stranded DNA.
- site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant peptide.
- An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al. , Proc. Natl. Acad. Sci. (USA) 75:5765 (1978).
- This primer is then annealed with the single-stranded protein-sequence-containing vector, and subjected to DNA- polymerizing enzymes such as E. coli polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand.
- a mutated sequence and the second strand bears the desired mutation.
- This heteroduplex vector is then used to transform appropriate cells and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.
- the mutated protein region may be removed and placed in an appropriate vector for protein production, generally an expression vector of the type that may be employed for transformation of an appropriate host.
- An example of a terminal insertion includes a fusion of a signal sequence, whether heterologous or homologous to the host cell, to the N- terminus of the peptide molecule to facilitate the secretion of mature peptide molecule from recombinant hosts.
- variants are those in which at least one amino acid residue in the peptide molecule, and preferably only one, has been removed and a different residue inserted in its place. Such substitutions preferably are made in accordance with the following list when it is desired to modulate finely the characteristics of a peptide molecule.
- Substantial changes in functional or immunological properties are made by selecting substitutions that are less conservative that those in the above list, that is, by selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the molecule at the target site; or (c) the bulk of the side chain.
- substitutions that in general are expected to those in which (a) glycine and/or proline is substituted by another amino acid or is deleted or inserted; (b) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; (c) a cysteine residue is substituted for (or by) any other residue; (d) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) a residue having an electronegative charge, e.g., glutamyl or aspartyl; or (e) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e
- deletions and insertions, and substitutions in particular are not expected to produce radical changes in the characteristics of the peptide molecule.
- substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays.
- a variant typically is made by site-specific mutagenesis of the peptide molecule-encoding nucleic acid, expression of the variant nucleic acid in recombinant cell culture, and, optionally, purification from the cell culture, for example, by immunoaffinity adsorption on an anti-peptide antibody column (to absorb the variant by binding it to at least one epitope).
- TCR V ⁇ l2.1 + T cells The relative percentage of TCR V ⁇ l2.1 + T cells in rheumatoid arthritis patients was assessed using V ⁇ l2.1-specific mAb 6D6 in both CD4 + and CD8 + subsets by two-color staining and flow cytometry.
- V ⁇ 12.1 -normal contained percentages of TCR V ⁇ l2.1 + , CD8 + T cells (mean of 3.6%, range 1.0% to 7.0%) which was similar to those found in normal subjects (Figure 2) (Der Simonian et al, J. Exp. Med. 174:639 (1991)).
- V ⁇ l2.1-elevated had much higher percentages of V ⁇ l2.1 + T cells (mean value of 22%, range 8.0% to 43 %) in the CD8 + subset.
- This group of patients contained greater than 7.5 % of V ⁇ l2.1 bearing CD8 + T cells (above two standard deviations (7.3%) from the mean (3.6%) of V ⁇ 12.1 -normal and healthy controls).
- Each of the nine patients in this V ⁇ l2.1-elevated group contained 43%, 28%, 26%, 22%, 21 %, 20%, 18%, 12%, 10% and 8.5 % V ⁇ l2.1 bearing CD8 + T cells, respectively.
- V ⁇ l2.1 + T cells The high percentages of V ⁇ l2.1 + T cells in patients was a relatively stable phenomenon as tested over one or two year period showed consistent levels. For instance, the V ⁇ l2.1 percentage in patient #3 (MG) was 26.5% (10/89), 22.5% (5/91), and 28.5 % (6/91) and for patient #4 (AL) was 26.5% (6/91) and 19% (11/91).
- T o gain insight into the basis for the V ⁇ l2.1 + T cell expansion in rheumatoid arthritis, V ⁇ l2.1 transcripts from positively selected CD8 + T cells were cloned and sequenced. In each of the three patients analyzed, distinct, repeated V ⁇ l2.1 containing sequences corresponding to functional TCR a-chain transcripts were identified. For example, in patient 1 where 43% of the
- CD8 + T cells were V ⁇ l2.1 + , all 15 DNA clones analyzed had identical sequences. Similarly, 9 of 16 (56%) V ⁇ l2.1 containing DNA clones were identical in patient #2, where 26 % of COB' T cells were V ⁇ l2.1 + . In patient 3, where 28% of CD8 + T cells were V ⁇ l2.1 + , 2 distinct sequences which were repeated were identified. One sequence was represented in 16 of 23
- V ⁇ l2.1 + T cells expressed mostly IL-2R ⁇ - chain. No significant number of freshly isolated V ⁇ l2.1 + T lymphocytes expressed the "high affinity" IL-2R ad-chains.
- transferrin receptor on V ⁇ l2.1 + T cells also was analyzed. However, no detectable levels were found.
- CD45RO was expressed on majority of the V ⁇ l2.1 + T cells indicating a memory phenotype.
- V ⁇ l2.1 + T cells (10% to 30%) expressed HLA-1 and HLA-DR, suggesting ongoing activation for a fraction of these cells.
- MHC alleles present in the V ⁇ l2.1-elevated group were examined and compared to the group of rheumatoid arthritis patients lacking expansion of V ⁇ l2.1 bearing T cells ( Figure 5). Both the V ⁇ 12.1 -elevated and the V ⁇ l2.1-normal group expressed HLA-DR1 and -DR4 alleles as expected for adult rheumatoid arthritis patients.
- the frequency of HLA DQw2 was increased as it was found in 6 of 7 (86%) of the patients ( Figure 5).
- the frequency for the DQw2 (DQB/0201) encoding allele, linked with DR3-(DQA1/0501) and DR7-(DQA1/0201) extended haplotype is approximately one in three (depending on the ethnic background), and a little less than 1 in 3 of the V ⁇ l2.1-normal group were DQw2 positive.
- T cells in rheumatoid arthritis that were encoded by V ⁇ l2.1 gene segment rearrangement to Jl 1 genes containing the pro-tyr dipeptide. These populations were readily detected using the simple screening technique of mAb staining and flow cytometry, which allowed examination of a relatively large number of subjects. The expansions found were present in approximately 1 of 6 (19%) patients and only in the CD811 population of (peripheral blood) T cells. It is widely assumed that the clinical diagnosis of rheumatoid arthritis may include at least several specific diseases.
- V ⁇ 12.1 -elevated group of rheumatoid arthritis patients represents a subset defined by an immunologic aberration, the expansion of V ⁇ l2.1 bearing CDB T cells and the increased association of the HLA DQw2 haplotype.
- This group of patients did not differ from the V ⁇ l2.1-normal group of R3 patients in their clinical parameters (such as ESR, PCV).
- HLA-00 molecules in the expansion of COB' T cells may be important in autoimmune regulation or immunoglobulin production as demonstrated in a different system by Salgame et al , Proc. Natl. Acad. Sci. USA 88:2598 (1991). Whether the V ⁇ l2.1 + T cell population or the antigen to which it responds are critical to the process of rheumatoid arthritis remains to be determined. However, this finding of striking clonal expansions that account for one fifth to nearly one half of the CD8 T cells in the periphery of a group of patients with rheumatoid arthritis is highly relevant to the diagnosis of rheumatoid arthritis and yields insight into the pathophysiology of the disease process.
- ADDRESSEE Sterne, Kessler, Goldstein & Fox
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94341892A | 1992-09-14 | 1992-09-14 | |
US943418 | 1992-09-14 | ||
PCT/US1993/008644 WO1994006823A1 (fr) | 1992-09-14 | 1993-09-14 | Reactifs et procedes de traitement de l'arthrite rhumatoide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0666867A1 true EP0666867A1 (fr) | 1995-08-16 |
EP0666867A4 EP0666867A4 (fr) | 1997-08-27 |
Family
ID=25479625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93921548A Withdrawn EP0666867A4 (fr) | 1992-09-14 | 1993-09-14 | Reactifs et procedes de traitement de l'arthrite rhumatoide. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0666867A4 (fr) |
JP (1) | JPH08501554A (fr) |
AU (1) | AU4920093A (fr) |
CA (1) | CA2144044A1 (fr) |
WO (1) | WO1994006823A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115744A (en) * | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
US6034064A (en) * | 1995-04-07 | 2000-03-07 | Hoechst Pharmaceuticals & Chemicals K.K. | Peptides and therapeutic agent for autoimmune diseases containing the same |
JPH08333390A (ja) * | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
PL345958A1 (en) * | 1998-07-23 | 2002-01-14 | Akzo Nobel Nv | Novel peptides for use in immunotherapy of autoimmune diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992012996A2 (fr) * | 1991-01-22 | 1992-08-06 | The Immune Response Corporation | Vaccination et procedes de lutte contre des maladies causees par des reactions pathogenes de populations de lymphocytes t |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI891226L (fi) * | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
-
1993
- 1993-09-14 EP EP93921548A patent/EP0666867A4/fr not_active Withdrawn
- 1993-09-14 AU AU49200/93A patent/AU4920093A/en not_active Abandoned
- 1993-09-14 CA CA002144044A patent/CA2144044A1/fr not_active Abandoned
- 1993-09-14 WO PCT/US1993/008644 patent/WO1994006823A1/fr not_active Application Discontinuation
- 1993-09-14 JP JP6508239A patent/JPH08501554A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992012996A2 (fr) * | 1991-01-22 | 1992-08-06 | The Immune Response Corporation | Vaccination et procedes de lutte contre des maladies causees par des reactions pathogenes de populations de lymphocytes t |
Non-Patent Citations (2)
Title |
---|
J. EXP. MED., vol. 177, no. 6, June 1993, pages 1623-1631, XP000653034 DERSIMONIAN H. ET AL.: "Clonal V-alpha-12.1+ T-cell expansions in the peripheral blood of rheumatiod arthritis patients" * |
See also references of WO9406823A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994006823A1 (fr) | 1994-03-31 |
AU4920093A (en) | 1994-04-12 |
CA2144044A1 (fr) | 1994-03-31 |
JPH08501554A (ja) | 1996-02-20 |
EP0666867A4 (fr) | 1997-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU635202B2 (en) | Anti-t-cell receptor determinants as autoimmune disease treatment | |
Martin et al. | Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis | |
EP1301202B1 (fr) | Molecules du cmh genetiquement modifiees | |
Khoury et al. | Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. | |
Karin et al. | Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. | |
US6207645B1 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations | |
AU651350B2 (en) | Multiple sclerosis T-cell receptor | |
US7972848B2 (en) | Isolation and identification of cross-reactive T cells | |
Zagon et al. | Increased frequency of Vβ17‐positive T cells in patients with rheumatoid arthritis | |
CA2110055C (fr) | Utilisation de peptides du recepteur de lymphocytes t contre les maladies du systeme immunitaire | |
US6221352B1 (en) | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells | |
EP0527199B2 (fr) | Compositions pour la mise en oeuvre d'une méthode pour le traitement d'un patient souffrant de sclérose en plaques | |
Steinman | Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire | |
EP0286447A2 (fr) | Méthode et composés pour le traitement prophylactique des maladies autoimmunes | |
AU669329B2 (en) | Method of modulating mammalian T-cell response | |
WO1994006823A1 (fr) | Reactifs et procedes de traitement de l'arthrite rhumatoide | |
US6413516B1 (en) | Peptides and methods against psoriasis | |
EP0602178A1 (fr) | Therapie de la polyarthrite rhumatoide basee sur le recepteur de lymphocytes t | |
Chan et al. | Usage of vβ3. 3 T‐cell receptor by myelin basic protein‐specific encephalitogenic T‐cell lines in the Lewis rat | |
Chen et al. | Oligoclonal expansion of T cell receptor V beta 2 and 3 cells in the livers of mice with graft-versus-host disease | |
AU697910C (en) | Peptides and methods against psoriasis | |
Eibl et al. | Symposium in Immunology I and II | |
Simpson | Minor transplantation antigens | |
Bauer et al. | Workshop N Autoimmunity | |
Frater | A functional analysis of HLA-DQ using transgenic models |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950413 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: C07K 5/04 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19970623 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19970708 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |